These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci. Shigeoka AO; Jensen CL; Pincus SH; Hill HR J Infect Dis; 1984 Jul; 150(1):63-70. PubMed ID: 6379061 [TBL] [Abstract][Full Text] [Related]
43. Decreasing mortality in neonates with early-onset group B streptococcal infection: reality or artifact. Pyati SP; Pildes RS; Ramamurthy RS; Jacobs N J Pediatr; 1981 Apr; 98(4):625-7. PubMed ID: 7009821 [No Abstract] [Full Text] [Related]
44. Demonstration of circulating group B streptococcal immune complexes in neonates with meningitis. Vallejo JG; Baker CJ; Edwards MS J Clin Microbiol; 1994 Sep; 32(9):2041-5. PubMed ID: 7814522 [TBL] [Abstract][Full Text] [Related]
45. [B Streptococcus agalactiae infection in neonates (author's transl)]. Paris A; Salle B; Putet G; Fleurette J; Monnet P Ann Pediatr (Paris); 1982 Feb; 29(2):121-4. PubMed ID: 7036828 [No Abstract] [Full Text] [Related]
46. Group B streptococcal infection in humans. Wilkinson HW Annu Rev Microbiol; 1978; 32():41-57. PubMed ID: 360972 [No Abstract] [Full Text] [Related]
47. Functional properties of anti-group B streptococcal monoclonal antibodies. Harris MC; Douglas SD; Kolski GB; Polin RA Clin Immunol Immunopathol; 1982 Sep; 24(3):342-50. PubMed ID: 6813008 [No Abstract] [Full Text] [Related]
48. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody. Kim KS; Wass CA; Hong JK; Concepcion NF; Anthony BF Pediatr Res; 1988 Nov; 24(5):628-32. PubMed ID: 3060825 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of intravenous immunoglobulin (Sandoglobulin) in neonates. Weisman LE; Fischer GW; Hemming VG; Peck CC Pediatr Infect Dis; 1986; 5(3 Suppl):S185-8. PubMed ID: 3520504 [TBL] [Abstract][Full Text] [Related]
50. Group B Streptococcus: developing a correlate of protection for a vaccine against neonatal infections. Dangor Z; Lala SG; Kwatra G; Madhi SA Curr Opin Infect Dis; 2016 Jun; 29(3):262-7. PubMed ID: 26926474 [TBL] [Abstract][Full Text] [Related]
51. Opsonic and protective activity of immunoglobulin, modified immunoglobulin, and serum against neonatal Escherichia coli K1 infection. Bortolussi R; Fischer GW Pediatr Res; 1986 Feb; 20(2):175-8. PubMed ID: 3511443 [TBL] [Abstract][Full Text] [Related]
52. The role of complement and antibody in opsonophagocytosis of type II group B streptococci. Baker CJ; Webb BJ; Kasper DL; Edwards MS J Infect Dis; 1986 Jul; 154(1):47-54. PubMed ID: 3519791 [TBL] [Abstract][Full Text] [Related]
53. Response to type III polysaccharide in women whose infants have had invasive group B streptococcal infection. Baker CJ; Rench MA; Kasper DL N Engl J Med; 1990 Jun; 322(26):1857-60. PubMed ID: 2190087 [No Abstract] [Full Text] [Related]
54. Antibody responses in invasive group B streptococcal infection in adults. Wessels MR; Kasper DL; Johnson KD; Harrison LH J Infect Dis; 1998 Aug; 178(2):569-72. PubMed ID: 9697746 [TBL] [Abstract][Full Text] [Related]
55. Immunofluorescence in group B streptococcal infection and idiopathic respiratory distress syndrome. Pinnas JL; Strunk RC; Fenton LJ Pediatrics; 1979 Apr; 63(4):557-61. PubMed ID: 375179 [TBL] [Abstract][Full Text] [Related]
56. Human antibody to the group-specific polysaccharide of group B Streptococcus. Anthony BF; Concepcion NF; Concepcion KF J Infect Dis; 1985 Feb; 151(2):221-6. PubMed ID: 3881538 [TBL] [Abstract][Full Text] [Related]
57. IgG subclasses to group B streptococci in normals, colonized woman and IgG2 subclass-deficient patients. Quinti I; Papetti C; von Hunolstein C; Orefici G; Aiuti F Monogr Allergy; 1988; 23():148-55. PubMed ID: 3290659 [No Abstract] [Full Text] [Related]
58. Intravenous gamma-globulin in the treatment of neonatal sepsis with special reference to group B streptococci and pharmacokinetics. Christensen KK; Christensen P Pediatr Infect Dis; 1986; 5(3 Suppl):S189-92. PubMed ID: 3520505 [No Abstract] [Full Text] [Related]
59. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648 [TBL] [Abstract][Full Text] [Related]
60. Group B streptococcal disease. In neonates and infants. Tseng PI; Kandall SR N Y State J Med; 1974 Nov; 74(12):2169-73. PubMed ID: 4612412 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]